The IL15 Superagonist ALT-803 plus Nivolumab Has Antitumor Activity [Research Watch]

Nivolumab in combination with ALT-803 is tolerable and achieves responses in patients with NSCLC.

from Cancer via ola Kala on Inoreader https://ift.tt/2JIayA0
via IFTTT